A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye. Our product candidate, KPI-012, which we acquired from Combangio, Inc., or Combangio, on November 15, 2021, is a mesenchymal stem cell secretome, or MSC-S, and is currently in clinical development for the treatment of persistent corneal epithelial defects, or PCED, a rare disease of impaired corneal healing. Based on the positive results of a Phase 1b clinical safety and efficacy trial of KPI-012 in patients with PCED, along with favorable preclinical safety and efficacy results, we submitted an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, which was accepted in December 2022.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | - |
| Net Income | -36M | -42M | -45M | -143M | -104M | -94M |
| EPS | $-5.64 | $-17.35 | $-29.48 | $-108.32 | $-99.50 | $-138.00 |
| Free Cash Flow | 0 | -29M | -79M | -109M | -93M | -94M |
| ROIC | -88.2% | -56.0% | -78.8% | -73.8% | -60.6% | -93.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 5.22 | 2.53 | 4.72 | 0.73 | 2.41 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -38M | -40M | -82M | -130M | -96M | -88M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -318.7% | -236.2% | -848.6% | -104.3% | -317.8% |
| Shares Outstanding | 8M | 2M | 2M | 1M | 1M | 1M |
| Metric | 2016 | 2017 | 2019 | 2020 | 2021 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0 | 0 | N/A | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 25M | 29M | 27M | 18M | 12M | 18M | 19M | 24M |
| SG&A | 7.6M | 11M | 65M | 81M | 105M | 65M | 21M | 18M |
| EBIT | -33M | -40M | -88M | -96M | -130M | -82M | -40M | -38M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -33M | -42M | -94M | -104M | -143M | -45M | -42M | -36M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 47M | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -70.5% | -41.5% | -93.5% | -60.6% | -73.8% | -78.8% | -56.0% | -88.2% |
| ROE | N/A | -4403.9% | -317.8% | -104.3% | -848.6% | -236.2% | -318.7% | 0.0% |
| ROA | -71.6% | -52.0% | -61.1% | -47.1% | -102.3% | -51.6% | -59.1% | -143.2% |
| Cash Flow | ||||||||
| Op. Cash Flow | -27M | -34M | -93M | -91M | -108M | -79M | -28M | -32M |
| Free Cash Flow | -28M | -35M | -94M | -93M | -109M | -79M | -29M | 0 |
| Owner Earnings | -30M | -38M | -104M | -105M | -125M | -86M | -36M | -41M |
| CapEx | 153K | 480K | 1.3M | 1.9M | 886K | 313K | 610K | 0 |
| Maint. CapEx | 297K | 287K | 843K | 912K | 975K | 537K | 303K | 332K |
| Growth CapEx | 0 | 193K | 492K | 1.0M | 0 | 0 | 307K | 0 |
| D&A | 297K | 287K | 843K | 912K | 975K | 537K | 303K | 332K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.1M | 3.6M | 10.0M | 13M | 16M | 7.0M | 7.5M | 8.7M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -81M | -204M | -99M | -81M | -105M | -93M | -63M | 43M |
| Cash & Equiv. | 45M | 115M | 85M | 77M | 92M | 70M | 51M | 42M |
| Long-Term Debt | 9.1M | 12M | 71M | 72M | 79M | 38M | 34M | 28M |
| Debt/Equity | -0.12 | 0.28 | 2.41 | 0.73 | 4.72 | 2.53 | 5.22 | 0.00 |
| Interest Coverage | -42.6 | -39.1 | -10.4 | -11.2 | -15.5 | -11.2 | -6.8 | -6.8 |
| Equity | -88M | 90M | 30M | 100M | 17M | 19M | 7.5M | -8.7M |
| Total Assets | 46M | 116M | 154M | 222M | 139M | 87M | 56M | 25M |
| Total Liabilities | 16M | 26M | 125M | 122M | 123M | 68M | 48M | 34M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -92M | -134M | -295M | -400M | -542M | -587M | -629M | -696M |
| Working Capital | 40M | 101M | 81M | 149M | 87M | 60M | 45M | -8.3M |
| Current Assets | 46M | 115M | 105M | 171M | 124M | 86M | 53M | 24M |
| Current Liabilities | 5.5M | 14M | 25M | 22M | 37M | 26M | 8.3M | 33M |
| Per Share Data | ||||||||
| EPS | -1,403.50 | -305.50 | -138.00 | -99.50 | -108.32 | -29.48 | -17.35 | -5.64 |
| Owner EPS | -60.50 | -77.28 | -151.47 | -100.06 | -95.17 | -56.86 | -14.68 | -5.00 |
| Book Value | -178.70 | 182.60 | 43.43 | 95.37 | 12.76 | 12.48 | 3.09 | -1.06 |
| Cash Flow/Share | -55.68 | -69.43 | -135.62 | -86.50 | -82.21 | -51.90 | -11.48 | -4.33 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.5M | 0.5M | 0.7M | 1.0M | 1.3M | 1.5M | 2.4M | 8.2M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.2 | 4.3 | 3.8 | 4.7 | 1.0 | 2.4 | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -7.4% | -73.8% | -24.3% | -138.1% | -417.5% | -157.9% | N/A |
| Market Cap | N/A | 467M | 128M | 382M | 79M | 19M | 18M | 1.9M |
| Avg. Price | N/A | 1,010.04 | 280.49 | 430.40 | 244.56 | 27.20 | 13.43 | 0.23 |
| Year-End Price | N/A | 950.00 | 186.50 | 364.00 | 60.00 | 12.48 | 7.43 | 0.23 |
KALA BIO, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
KALA BIO, Inc. (KALA) has a 5-year average return on invested capital (ROIC) of -72.5%. This is below average and may indicate limited pricing power.
KALA BIO, Inc. (KALA) has a market capitalization of $2M. It is classified as a small-cap stock.
KALA BIO, Inc. (KALA) does not currently pay a regular dividend.
KALA BIO, Inc. (KALA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
KALA BIO, Inc. (KALA) generated $-29 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
KALA BIO, Inc. (KALA) has a debt-to-equity ratio of 5.22. This indicates higher leverage, which may increase financial risk.
KALA BIO, Inc. (KALA) reported earnings per share (EPS) of $-17.35 in its most recent fiscal year.
KALA BIO, Inc. (KALA) has a return on equity (ROE) of -318.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for KALA BIO, Inc. (KALA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KALA BIO, Inc. (KALA) has a book value per share of $3.09, based on its most recent annual SEC filing.